HAP

Radiology Associates of Keene Contracts with Healthcare Administrative Partners for Comprehensive Revenue Cycle Services

Retrieved on: 
Tuesday, October 17, 2023
Other Health, Hospitals, Health, Radiology, Practice Management, Radiology Associates Field at Jackie Robinson Ballpark, Practice management, Partner, HAP, Hospital

Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Radiology Associates of Keene in Keene, NH to its roster of radiology revenue cycle management clients.

Key Points: 
  • Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Radiology Associates of Keene in Keene, NH to its roster of radiology revenue cycle management clients.
  • Under the terms of the agreement, HAP will perform all core revenue cycle services on behalf of Radiology Associates of Keene including billing, coding, carrier credentialing, business intelligence, and MIPS Measure Assurance Services.
  • According to Dr. Paul Koutras, President of Radiology Associates of Keene, “There were several attributes we searched for in a revenue cycle partner including an expertise in radiology, an experienced and tenured team, and an impeccable record of customer satisfaction.
  • Our search ended with HAP because their team had all those critical elements and more.

Global Regenerative Thermal Oxidizer (RTO) Markets, 2021-2031 with 2022 as the Base Year - Rotary Regenerative Thermal Oxidizers Emerge as Preferred Choice for Large Industrial Applications

Retrieved on: 
Thursday, October 12, 2023
Industrial Emissions Directive, Food, European, Organic compound, Compact, Ship, VOC, CECO Environmental, Intelligence, Automation, Volatile organic compound, Porter's five forces analysis, Honeywell, HAP, Internet of things, Artificial intelligence, EPA, Growth, Maintenance, Air pollution, Dürr AG, IED, Monolithic kernel, Public utility, Pet industry, Retail, Electric power, Customer service, Coal, Fine chemical, Environmental remediation, Fertilizer

One of the primary drivers propelling the demand for Regenerative Thermal Oxidizer (RTO) systems is the growing global concern over air pollution.

Key Points: 
  • One of the primary drivers propelling the demand for Regenerative Thermal Oxidizer (RTO) systems is the growing global concern over air pollution.
  • The global regenerative thermal oxidizer (RTO) market is highly competitive, with key players focusing on strategies like product innovation, partnerships, and acquisitions.
  • The regenerative thermal oxidizer (RTO) market can also be segmented by product type into rotary regenerative thermal oxidizer and compact type regenerative thermal oxidizer.
  • In terms of revenue, the rotary regenerative thermal oxidizer segment held the largest share of the market in 2022.

PatientPay Announces Session Presentation at 2023 HBMA Fall Revenue Cycle Management Conference

Retrieved on: 
Thursday, September 21, 2023
Other Health, Insurance, Software, Networks, Finance, Electronic Commerce, Data Management, Professional Services, Technology, Practice Management, Mobile, Wireless, Physical Therapy, Managed Care, General Health, Payments, Health, Health Technology, Health Insurance, Acceleration, Organization, Knowledge, HAP, SVP, Collection, Conference, Nursing, Health insurance

PatientPay , the leading patient payments partner for acute, ambulatory, and specialty care, today announced that Pete Heydt, President of PatientPay and Susan Bailie, SVP of Operations at Healthcare Administrative Partners (HAP) will be hosting a session at the 2023 Healthcare Business Management Association (HBMA) Fall Conference titled “More Effective Strategies for Solving Patient Billing and Collections.” Celebrating 30 years, the HBMA Fall conference will be held Sept. 26-28, 2023 in Indianapolis, IN.

Key Points: 
  • PatientPay , the leading patient payments partner for acute, ambulatory, and specialty care, today announced that Pete Heydt, President of PatientPay and Susan Bailie, SVP of Operations at Healthcare Administrative Partners (HAP) will be hosting a session at the 2023 Healthcare Business Management Association (HBMA) Fall Conference titled “More Effective Strategies for Solving Patient Billing and Collections.” Celebrating 30 years, the HBMA Fall conference will be held Sept. 26-28, 2023 in Indianapolis, IN.
  • During the session, attendees will be educated on concepts and tactics that financial and operational executives can use to positively impact financial results for more effective patient billing and payment experiences.
  • PatientPay’s collection rate (43%) is higher than the market (20%) with the average payment turnaround being within 14 days.
  • “At PatientPay, our clients have seen a vast increase in the amount of patient payments and an acceleration in the time it takes to collect payments ultimately lowering overall costs,” says Pete Heydt, President of PatientPay.

Hampton Roads Radiology Associates Selects Healthcare Administrative Partners as Comprehensive Revenue Cycle & Practice Management Services Provider

Retrieved on: 
Thursday, September 14, 2023
Radiology, Hospitals, Health, Practice Management, HAP, Hospital, Practice management, Practice, Associate, Partner, Medical imaging

Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Hampton Roads Radiology Associates (HRRA) to its roster of radiology revenue cycle and practice management clients.

Key Points: 
  • Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Hampton Roads Radiology Associates (HRRA) to its roster of radiology revenue cycle and practice management clients.
  • There were several requirements that Hampton Roads Radiology Associates were looking for in a revenue cycle management partner.
  • According to Jamie Walker, Practice Manager, at HRRA, “The ability to work with one vendor for revenue cycle and practice/financial management services was an important differentiator.
  • We look forward to working with Hampton Roads Radiology Associates and cultivating this new partnership.”

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Retrieved on: 
Tuesday, September 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ketan, Pharma, Naloxone, Oxycodone, Food and Drug Administration, Opioid use disorder, ADHD, DSM-IV codes, OUD, VAS, FQ, Physical dependence, II, Pain, Visual analogue scale, NOP, Patient, Risk, MOP, Neuropathic pain, Pain management, Addiction, Drug, HAP, FDA, Tramadol, Food, Pharmaceutical industry, Tris

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.
  • The findings will be shared on Thursday, September 7, in a poster presentation at the 2023 PAINWeek conference in Las Vegas.
  • Study participants randomly received a single dose of placebo, cebranopadol 600 μg, cebranopadol 1000 μg, tramadol IR 600 mg or oxycodone IR 40 mg.
  • The difference between the good effects and bad effects of drugs have been linked to their abuse potential.

Forbright Bank Finances $6.4 Million Affordable Housing Project in Massachusetts

Retrieved on: 
Thursday, August 24, 2023
Residential Building & Real Estate, Banking, Social Services, Construction & Property, Professional Services, White House, Federal Government, State, Local, Public Policy, Government, Environment, Finance, Sustainability, United States Department of Housing and Urban Development, Partnership, Housing, U.S. Department of Housing and Urban Development, Office of Inspector General, United States Secretary of Housing and Urban Development, FDIC, HUD, Equal housing lender, MIP, Mortgage assumption, HAP, Commercial property, Real estate

Forbright Bank, a nationwide full-service bank helping accelerate the transition to a sustainable economy, utilized its newly established Housing and Urban Development (HUD) Lending platform to provide a $6.4 million loan to Willow Apartments in Lynn, Massachusetts.

Key Points: 
  • Forbright Bank, a nationwide full-service bank helping accelerate the transition to a sustainable economy, utilized its newly established Housing and Urban Development (HUD) Lending platform to provide a $6.4 million loan to Willow Apartments in Lynn, Massachusetts.
  • It’s owned and managed by an affordable housing developer with decades of experience developing, owning, and managing projects in the New England region.
  • The project has 44 units, 43 of which are covered by a Project Based Section 8 Housing Assistance Payments Contract (HAP Contract).
  • Forbright Bank ( www.forbrightbank.com ), Member FDIC, Equal Housing Lender, is a full-service bank taking action to decarbonize the economy.

Health Alliance Plan and CareSource Secure Regulatory Approval for Medicaid Joint Venture in Michigan

Retrieved on: 
Thursday, August 17, 2023
Michigan Department of Licensing and Regulatory Affairs, Medicare Advantage, Medicaid, Partnership, Financial services, Health equity, Medicare, Name, Physician, MNsure, HAP, Health insurance marketplace, Henry Ford Health, Michigan Department of Insurance and Financial Services, Michigander, CareSource, Nursing, Health insurance, Management

DETROIT, Aug. 17, 2023 /PRNewswire/ -- Health Alliance Plan (HAP), a Michigan-based nonprofit health plan, and CareSource, an Ohio-based nonprofit managed care health plan, received regulatory approval to move forward with their joint venture after a comprehensive review by state and federal regulatory agencies. Operating as "HAP CareSource," the entities will develop new programs and products to better serve the people of Michigan and provide expansive and higher quality health care coverage to more residents across the state.

Key Points: 
  • Leading health care providers operating as "HAP CareSource" to create innovative programs focused on health equity.
  • DETROIT, Aug. 17, 2023 /PRNewswire/ -- Health Alliance Plan (HAP), a Michigan-based nonprofit health plan, and CareSource, an Ohio-based nonprofit managed care health plan, received regulatory approval to move forward with their joint venture after a comprehensive review by state and federal regulatory agencies.
  • HAP, one of the most trusted names in Michigan health insurance, currently provides Medicaid coverage to 43,000 HAP Empowered members in Michigan, along with Medicare Advantage and commercial plans.
  • CareSource, one of the nation's largest managed Medicaid and government-sponsored health care organizations, serves 2.3 million members in Ohio, Indiana, Kentucky, Georgia, Arkansas, North Carolina and West Virginia, including Medicaid, Health Insurance Marketplace and Medicare products.

DCHFA closes July with the financing of 673 affordable apartments in Wards 6 and 8

Retrieved on: 
Thursday, August 3, 2023
Partnership, Browne's Addition, Spokane, Golden Rule, Capital market, Village, PSH, Parkland, Rehabilitation, Tenant, Northwest One Library, CSG, Acquisition, Temple Court railway station, NoMa, Agency, Associate, Economic development, AMI, Ward, LIHTC, HAP, NCI, Security (finance), Huntington Village Historic District, D.C

The second deal that closed on July 28th was the financing of Northwest One Phase II.

Key Points: 
  • The second deal that closed on July 28th was the financing of Northwest One Phase II.
  • Additional financing for Northwest One is being provided by a $39 million DMPED NCI loan.
  • “The financing of nearly 700 units in a week, demonstrates the robust activity of DCHFA’s multifamily pipeline,” stated Christopher E. Donald, Executive Director/CEO, DCHFA.
  • The Villages at Parklands Phase I is comprised of two apartment communities, Huntington Village Apartments and Orchard Park Village Apartments.

Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

Retrieved on: 
Monday, July 17, 2023
Aureus, Gram-positive bacteria, S. aureus, CAP, European Medicines Agency, SOC, S, Staphylococcus aureus, Trial of the century, EMA, US, Standard of care, Patient, VAP, Immune system, LOS, HAP, FDA, Pneumonia, Vaccine, Pharmaceutical industry

Agreement to the proposed expansion of the confirmatory Phase 3 study in S. aureus ventilator associated pneumonia (VAP) patients to include S. aureus pneumonia in ventilated hospital acquired pneumonia (HAP) and ventilated community acquired pneumonia (CAP) patients.

Key Points: 
  • Agreement to the proposed expansion of the confirmatory Phase 3 study in S. aureus ventilator associated pneumonia (VAP) patients to include S. aureus pneumonia in ventilated hospital acquired pneumonia (HAP) and ventilated community acquired pneumonia (CAP) patients.
  • Agreement on Clinical Cure of pneumonia on Day 21 as the primary efficacy endpoint, as in the first Phase 3 study ‘AR-301-002’.
  • “We are particularly gratified to reach concurrence, first with the FDA, and now with the EMA on the overall study design, endpoints, and patient populations,” said Aridis CEO Vu Truong.
  • “This provides for a globally harmonized clinical study and regulatory pathway to bring AR-301 to patients with high vulnerabilities to Staph.

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

Retrieved on: 
Wednesday, July 12, 2023
China Biologic Products, Biologics license application, Drug development, Food and Drug Administration Safety and Innovation Act, Innovation Act, QIDP, CAP, Infection, Omnibus spending bill, S, AMR, Staphylococcus, GAIN, Patient, Immunoglobulin G, VAP, Mab, Consolidated Appropriations Act, 2022, LOS, ICU, Saleh al Aridi, HAP, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Pneumonia, Food, Pharmaceutical industry, FDASIA

"Our AR-301 program will now benefit from the FDA's priority review, in addition to previously awarded Fast-Track status, allowing for accelerated drug development and regulatory review processes.

Key Points: 
  • "Our AR-301 program will now benefit from the FDA's priority review, in addition to previously awarded Fast-Track status, allowing for accelerated drug development and regulatory review processes.
  • This sought-after designation positions our AR-301 program extremely well as we continue to advance it through a confirmatory Phase 3 trial and license application."
  • AR-301 specifically targets S. aureus alpha-toxin, which has been implicated in the pathogenesis of pneumonia caused by S. aureus bacteria.
  • Aridis received positive feedback from the FDA in May 2023 on the Company's proposed single confirmatory Phase 3 study of AR-301.